Reparixin improves survival in critically ill and transplant patients: A meta-analysis.

Gioia Piersanti Giovanni LandoniTommaso ScquizzatoAlberto ZangrilloLorenzo Piemonti

Published in: European journal of clinical investigation (2023)

The findings of this meta-analysis indicate that reparixin, an anti-inflammatory drug, improved survival in critically ill or transplant patients (including both COVID-19 and non-COVID-19 patients) without increasing the risk of infection.

Keyphrases

systematic review
end stage renal disease
newly diagnosed
ejection fraction
anti inflammatory
prognostic factors
patient reported outcomes
emergency department
peritoneal dialysis
free survival